Informing the development of a standardised approach to measure antibiotic use in secondary care: a systematic review protocol by Patel, S et al.
1Patel S, et al. BMJ Open 2019;9:e026792. doi:10.1136/bmjopen-2018-026792
Open access 
Informing the development of a 
standardised approach to measure 
antibiotic use in secondary care: a 
systematic review protocol
Selina Patel,  1 Arnoupe Jhass,2 Susan Hopkins,3 Laura Shallcross1
To cite: Patel S, Jhass A, 
Hopkins S, et al.  Informing 
the development of a 
standardised approach to 
measure antibiotic use in 
secondary care: a systematic 
review protocol. BMJ Open 
2019;9:e026792. doi:10.1136/
bmjopen-2018-026792
 ► Prepublication history and 
additional material for this paper 
are available online. To view, 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2018- 026792).
Received 19 September 2018
Revised 9 April 2019
Accepted 11 April 2019
1Institute of Health Informatics, 
University College London, 
London, UK
2Department of Primary Care 
and Population Health, Institute 
of Epidemiology and Health 
Care, University College London, 
London, UK
3Public Health England, London, 
UK
Correspondence to
Selina Patel;  
 selina. patel. 17@ ucl. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction Ecological and individual-level evidence 
indicates that there is an association between level of 
antibiotic exposure and the emergence and spread of antibiotic 
resistance. The Global Point Prevalence Survey in 2015 
estimated that 34.4% of hospital inpatients globally received at 
least one antimicrobial. Antimicrobial stewardship to optimise 
antibiotic use in secondary care can reduce the high risk of 
patients acquiring and transmitting drug-resistant infections 
in this setting. However, differences in the availability of data 
on antibiotic use in this context make it difficult to develop a 
consensus of how to comparably monitor antibiotic prescribing 
patterns across secondary care. This review will aim to 
document and critically evaluate methods and measures to 
monitor antibiotic use in secondary care.
Methods and analysis We will search Medline (Ovid), 
Embase (Ovid), Cumulative Index to Nursing and Allied Health 
Literature, Cochrane Central Register of Controlled Trials 
and websites of key organisations for published reports 
where an attempt to measure antibiotic usage among adult 
inpatients in high-income hospital settings has been made. 
Two independent reviewers will screen the studies for 
eligibility, extract data and assess the study quality using the 
Newcastle-Ottawa scale. A description of the methods and 
measures used in antibiotic consumption surveillance will be 
presented. An adaptation of the Affordability, Practicability, 
Effectiveness, Acceptability, Side-effects Equity framework 
will be used to consider the practicality of implementing 
different approaches to measuring antibiotic usage in 
secondary care settings. A descriptive comparison of 
definitions and estimates of (in)appropriate antibiotic usage 
will also be carried out.
Ethics and dissemination Ethical approval is not required 
for this study as no primary data will be collected. The 
results will be published in relevant peer-reviewed journals 
and presented at relevant conferences or meetings where 
possible. This review will inform future approaches to scale 
up antibiotic consumption surveillance strategies to attempt 
to maximise impact through standardisation.
PrOsPErO registration number CRD42018103375
IntrOduCtIOn
It is estimated that by the year 2050, 10 million 
deaths per year will be attributable to anti-
microbial resistance (AMR).1 There is good 
evidence from ecological studies that at the 
population level higher rates of antibiotic resis-
tance are associated with high levels of antibi-
otic consumption.2 There are increasing data 
to indicate that antibiotic exposure promotes 
resistance at the individual level also.3 Nation-
ally aggregated antibiotic consumption across 
65 countries is estimated to range between 4.4 
and 64.4 defined daily doses (DDD) per 1000 
inhabitants per day.4 The Global Point Prev-
alence Survey estimated that 34.4% of adult 
inpatients admitted to 303 hospitals globally 
received at least one antimicrobial, and that 
8.4% of adult inpatients were treated with a 
systemic antibacterial for a healthcare associ-
ated infection(s).5 Antimicrobial stewardship 
(AMS) to optimise the use of antimicrobials 
and safely reduce the total quantity of antimi-
crobials consumed is a recognised approach 
to control the emergence and spread of AMR. 
Surveillance of antimicrobial consumption 
underpins the ability to monitor the impact 
of AMS interventions and to measure varia-
tion in appropriate/inappropriate antibiotic 
prescribing over time. Despite this, conven-
tional metrics of antibiotic usage which 
strengths and limitations of this study
 ► This study protocol follows the recommenda-
tions outlined in the Preferred Reporting Items for 
Systematic Review and Meta-analysis Protocols.
 ► This protocol has been registered on the International 
Prospective Register of Systematic Reviews.
 ► The selection of studies, data extraction and study 
quality assessments will be conducted by two inde-
pendent reviewers.
 ► The exclusion of studies which do not report the to-
tal number of patients may exclude very large-scale 
antibiotic consumption surveillance projects.
 ► The information available in some published stud-
ies may be too limited to assess surveillance meth-
odologies using the Affordability, Practicability, 
Effectiveness, Acceptability, Side-effects, Equity 
criteria.
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enable comparisons across settings in secondary care 
have not been established.6 In the currently published 
literature, there is also a lack of definitions or quantita-
tive estimates of inappropriate antibiotic consumption in 
secondary care.
Measuring antibiotic prescribing in secondary care
A range of strategies are being adopted to monitor and 
improve antibiotic prescribing in hospital. In Australia 
and England, surveillance systems have been established 
to measure antibiotic use in hospitals based on dispensing 
data from hospital pharmacies, converted into DDD.7 8 A 
DDD is the assumed average maintenance dose per day for 
a drug for its main indication in adults.9 DDDs are widely 
adopted to estimate quantities of antibiotic consump-
tion and enable comparisons across drugs. However, the 
denominator of this measure in secondary care varies to 
make estimates less comparable, for example: 1000 occu-
pied bed days, 1000 inhabitants, 1000 admissions.10–13 
This variation is likely to reflect differences in the avail-
ability of data across high-income secondary care settings. 
These metrics do not consider patient case-mix, nor is 
there is not a widely accepted methodology to apply to 
estimates to account for this. Consequently, any compar-
isons drawn between quantities of antibiotic usage across 
healthcare settings must be cautiously interpreted.
It is recommended that antimicrobial consumption 
surveillance should combine aggregate data with patient-
level data to better understand patterns of prescribing.4 
In secondary care, patient-level data on prescribing 
and prescribing associated factors are usually obtained 
through point prevalence surveys, representing a single 
point in time.14 However, secondary care is a dynamic 
setting and several clinicians may be involved in different 
stages of the prescribing process including: antibiotic 
initiation, treatment selection, clinical review, de-esca-
lation and cessation of treatment. This contrasts with 
primary care, where patients usually have a single consul-
tation which may result in an antibiotic prescription. 
This makes understanding patterns of prescribing within 
hospitals more difficult to map and highlights the useful-
ness of using patient-level prescribing data linked to the 
prescriber, to monitor patterns of antimicrobial usage 
and stewardship as patients move through the hospital.
Measuring antibiotic stewardship
In the UK, the Commissioning for Quality and Innova-
tion has established performance management targets 
to financially incentivise reductions in antibiotic use in 
primary and secondary care. This includes targets to 
promote prescribing review within 72 hours. In most 
hospitals, adherence to this target is monitored by 
auditing a sample of prescriptions.15 16 This approach is 
time consuming and cannot capture the range of factors 
that might have an important bearing on the quality of 
the review, such as patient characteristics or the seniority 
or specialty of individuals who were involved in the 
prescribing process. Such factors limit the ability to make 
inferences about the quality of AMS in different hospitals. 
Importantly existing measures provide little insight into 
where hospitals should target resources in their setting to 
have the greatest impact on antibiotic prescribing.
The National Antimicrobial Prescribing Survey (NAPS) 
measures similar antibiotic stewardship behaviours, 
however it goes further by estimating inappropriate 
prescribing. These data are collected through point 
prevalence surveys of all patients in the hospital where 
possible. Inappropriateness is defined in this survey as 
prescribing the wrong antibiotic spectrum, incorrect 
dose/frequency/duration/route and prescribing when 
an antimicrobial is not needed. Decisions on inappropri-
ateness are made by a multi-desciplinary clinical team’s 
assessment and are reported as prevalence of prescrip-
tions. In 2017, 17 366 patients were submitted to NAPS 
with 26 227 prescriptions from 314 participating hospi-
tals which were assessed for inappropriateness.17 This is a 
large data collection workload which, in Australia, is only 
a proportion of the NAPS and runs annually alongside 
NAUSP. It is also a methodology which could be subject 
to variation between auditors when assessing inappropri-
ateness of a broad range of prescriptions. Manual audits 
therefore seem labour-intensive and impractical for 
future attempts to scale up data collection of big, patient-
level datasets to understand more granular patterns of 
prescribing in secondary care over time.
Variations exist in the length of time between data 
collection and publication of results across surveillance 
programmes. The 2016 NAUSP data were published in 
2018, while the 2017 Swedish Antibiotic Utilisation and 
Resistance in Human Medicine (SWEDRES) and Swedish 
Veterinary Antibiotic Resistance Monitoring (SVARM) 
report published data collected in 2017 by the following 
year.10 13 This likely reflects extensive differences in 
the availability of data, surveillance infrastructure and 
the digital maturity of healthcare systems which can 
be observed across high-income countries. The wide-
spread establishment of electronic prescribing systems 
in the USA and the proposed investments in electronic 
prescribing systems in the UK and Australia, provides 
a potential opportunity to digitise systems to monitor 
antimicrobial usage and stewardship in secondary care 
and capture patient-level prescribing data over time to 
understand patterns of prescribing.18 19 This could enable 
descriptions of patterns of prescribing within hospitals to 
better document appropriate and inappropriate antibi-
otic usage in secondary care, however it would rely upon 
systems which facilitate good documentation of steward-
ship behaviours and prescriber decision making.
As high-income settings answer the WHO call to 
increase the availability of antimicrobial use data, there 
is a need to reach a consensus on how to interrogate 
these data and be able to draw comparisons between 
hospital sites.20 Previous attempts to establish a conven-
tional approach have failed to address all of the issues 
which we have already highlighted. Recently, two studies 
attempted to establish a consensus on quality and quantity 
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indicators for measuring antibiotic use in secondary care 
using systematic review and RAND-modified Delphi 
methods.21 22 However, neither study considered differ-
ences in the availability of data and resources between 
hospital settings, the practicability of implementing these 
indicators in surveillance strategies, or the strengths and 
limitations of the measures. To develop robust systems to 
monitor antibiotic usage in secondary care requires the 
development of simple measures which enable compari-
sons of antibiotic usage over time and across specialties. 
Critically, these measures must be co-developed with 
clinicians and pharmacists, and be based on data that are 
routinely available, since few hospitals have the resources 
to conduct regular audits of antimicrobial use.
The Affordability, Practicability, Effectiveness and 
cost-effectiveness, Acceptability, Side-effects/safety and 
Equity (APEASE) criteria for designing interventions 
provides a framework within which researchers can 
comprehensively consider the context-specific suitability 
of an intervention.23 It has been demonstrated repeat-
edly within the field in which it was developed to assess 
the suitability of behaviour change intervention func-
tions.24–27 It also provides the potential to be a useful tool 
when considering the complexities of identifying a suit-
able standardised antibiotic consumption surveillance 
methodology for the high-income secondary care setting.
This review will therefore study attempts to quan-
tify total systemic antibiotic use, appropriate antibiotic 
use and inappropriate use in high-income settings in 
secondary care. This review will provide a summary of 
the ways in which antibiotic use can be measured along-
side a narrative about the practicality of employing these 
metrics in secondary care based on an adaptation of the 
APEASE framework.
ObjECtIvEs
The aim of this review is to provide an outline of the 
methodologies to quantify antibiotic usage among inpa-
tients in secondary care. The objectives are:
 ► To identify the data sources and metrics which have 
most frequently been used to represent antibiotic 
usage in secondary care.
 ► To assess the suitability of antibiotic use surveil-
lance methodologies and metrics for use in routine 
surveillance of antibiotic usage based on the APEASE 
criteria.
 ► To document the variation in definitions and esti-
mates of appropriate and inappropriate antibiotic 
usage.
MEthOds
The following methods are based on the framework 
provided by the Preferred Reporting Items for Systematic 
review and Meta-Analysis Protocols (PRISMA-P) check-
list.28 This review began in August 2018 and we aim to 
complete the review by September 2019.
Eligibility criteria
Types of studies
Study inclusion criteria:
 ► Studies which quantify antibiotic usage in at least 100 
adult patients (aged >17 years) among inpatients in 
secondary care will be included.
 ► This review will include studies in the adult inpa-
tient, high-income secondary care setting as it is 
expected that quantities of antibiotic use and patterns 
of prescribing in non-adult inpatients is likely to be 
significantly different to those in adults.
 ► Studies which focus on antibiotic usage among indi-
viduals with specific conditions or specific demo-
graphic groups will be included.
 ► Those studies which do not provide enough infor-
mation for a complete assessment using the APEASE 
criteria will be included in the final review, but 
excluded from the APEASE criteria evaluation.
 ► This review will therefore include a range of study 
designs which are based on both observation and 
intervention, and which have attempted to estimate 
antibiotic usage in secondary care. 
Study exclusion criteria: 
 ► This review will not include trials of antibiotic thera-
pies in secondary care or reviews of the literature.
 ► Articles which describe a methodology for measuring 
antibiotic usage and which do not attempt to imple-
ment it to estimate antibiotic usage will be excluded.
 ► Articles which are not written in English language 
and are based on non-human participants will be 
excluded.
 ► If the number of adult inpatients included in the 
study is not stated, the article will be excluded from 
the review.
Types of participants
The study must be based on dispensing, prescribing, 
survey/audit or sales data collected from the inpatient 
secondary care setting. It is expected that hospitals in 
high-income settings will be very different to those in 
low-resource settings in both the availability of data and 
resources available for stewardship, therefore this review 
will focus on hospitals in high-income countries as classi-
fied by the World Bank only (online supplementary table 
S1).29 When the country is not classified in the World 
Bank lending groups, the article will be included if the 
gross national income per capita is US$12 056 or more. 
Articles must provide data which quantify antibiotic usage 
among adult patients (aged >17 years).
Types of interventions
This review will consider all attempts to measure anti-
biotic usage among at least 100 patients in the hospital 
inpatient setting.
Types of comparators
There are no comparison groups for this review as it is 
an exploration to identify how antibiotic usage has been 
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measured in secondary care and how this has been used 
to define and estimate appropriate and inappropriate 
antibiotic usage.
Types of outcome measures
Articles which report a measure of antibiotic usage in 
hospital will be included in this review.
Primary outcomes
 ► Data source used to represent antibiotic usage.
 ► Metrics which attempt to quantify antibiotic usage.
 ► An analysis of the suitability of existing metrics of anti-
biotic usage for use in routine practice to monitor anti-
biotic usage based on an adaptation of the APEASE 
framework (detailed in Data Synthesis).23
Secondary outcomes
 ► Quantitative definitions of appropriate and inappro-
priate antibiotic usage.
 ► Comparison of the definitions of appropriate and 
inappropriate prescribing in secondary care.
 ► Description of variations in estimates of appropriate 
and inappropriate prescribing in secondary care.
Information sources
Electronic searches
The following databases will be searched for relevant 
articles:
 ► Medline (Ovid);
 ► Embase (Ovid);
 ► Cumulative Index to Nursing and Allied Health 
Literature;
 ► Cochrane Central Register of Controlled Trials.
The search strategy will be developed in Medline and 
then adapted appropriately for use in each database. The 
search will be conducted across all databases on 2 August 
2018.
Website searches
In order to capture reports from the grey literature, 
the websites of relevant organisations will be searched 
(online supplementary table S2). The list of organisations 
expands on a list originally conceived by Stanić Benić et al. 
based on discussion between SP, AJ and LS.22 This review 
aims to consider the suitability of existing metrics of anti-
biotic usage in routine hospital surveillance of antibiotic 
usage; therefore it is essential that approaches to do this 
on a large scale such as through National Action Plans, 
which are often published in the grey literature, should 
be captured in our search. This search will be conducted 
in February 2019, the specific dates of which will be 
reported in the final review.
search strategy
The provisional search strategy is adapted from the work 
of Stanić Benić et al. based on four concepts: antibiotics, 
utilisation, measure, hospital (table 1).22 The search 
strategy will be established in Medline and then adapted 
to the other three databases included in the search. No 
additional restrictions will be placed on the search to 
maximise sensitivity.
study records
Data management
The articles will be uploaded from the relevant database 
to Mendeley reference manager software. The reports 
will be exported to the web-based, Evidence for Policy and 
Practice Information (EPPI) Reviewer 4 systematic review 
software which will be used to remove duplicate articles. 
Each stage of the screening process will be carried out in 
EPPI Reviewer 4 using a standardised form of article eligi-
bility. The online form for article eligibility will be piloted 
before the start of the screening process and amended as 
required to ensure it is fit for purpose. The data will be 
extracted and entered into a standardised, piloted, prec-
reated online data extraction form in EPPI Reviewer 4 in 
duplicate by two independent reviewers (SP and AJ).
Selection process
The unique articles captured by the search will undergo 
a title prescreening by a single reviewer (SP). The 
remaining articles will then be screened based on title 
and abstract by two independent reviewers in duplicate 
(SP and AJ); when study eligibility is not mutually agreed 
on or is ambiguous from the title and abstract only, the 
article will be admitted into the full-text review stage. The 
selected articles will undergo full-text review by two inde-
pendent reviewers in duplicate (SP and AJ). Any disagree-
ments between authors at any stage will be resolved 
through a third reviewer (LS). The reasons for the exclu-
sion of these studies from this review will be documented 
for reference and the study selection process will be 
presented as a PRISMA flow diagram.28
Data collection process
The data will be collected in duplicate by two independent 
reviewers (SP and AJ) from articles selected for inclusion 
in the review. The data will be entered into precreated, 
piloted forms on EPPI Reviewer 4: systematic review soft-
ware. Any disagreement will be resolved through consul-
tation with a third author (LS).
data items
We will extract data on:
 ► Study (study design, country, population, service 
setting such as size of hospital, objective).
 ► Data type used to describe antibiotic usage (data source, 
method of collection, frequency of the data collection, 
reason for data collection eg. national surveillance or 
research, who collected the data, level of detail in the 
data and data type).
 ► Metrics used to measure antibiotic usage (numerator, 
denominator, units (such as per admission), level at 
which the metric is presented (such as by specialty).
 ► Criteria used to define appropriate and inappropriate anti-
biotic usage.
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 ► Data type used to quantify appropriate and inappropriate 
antibiotic usage (data source, method of collection, 
level of detail in the data and data type).
 ► Quantitative estimates of appropriate and inappropriate 
antibiotic usage (numerator, denominator, units 
(such as per admission), level at which the metric is 
presented (such as by specialty) and what the metric 
is currently used for (such as national or hospital-level 
surveillance).
 ► Study quality and selection bias of those studies which 
provide an estimate of appropriate and inappropriate anti-
biotic usage (outlined under 'Assessment of risk of 
bias individual studies' section).
Outcomes prioritisation
The main outcome of this review is a description of 
the data sources and metrics which have been used to 
measure antibiotic usage and to define appropriate 
Table 1 Medline (Ovid) provisional search terms
Search concept Search terms
Antibiotic 1. Antibacterial agents/ad, dt, sd, tu, th, ut (Administration & Dosage, Drug Therapy, Supply & Distribution, 
Therapeutic Use, Therapy, Utilization)
2. Antibiotic prophylaxis/ec, mt, sn, td, ut (Economics, Methods, Statistics & Numerical Data, Trends, 
Utilization)
3. (anti?biotic? or anti?microbial? or anti?bacterial?).ab,ti.
4. 1 or 2 or 3
Utilisation 5. Drug prescriptions/
6. Drug utilization/
7. ‘Drug utilization review’/cl, ec, mt, st, sn, td, ut (Classification, Economics, Methods, Standards, Statistics 
& Numerical Data, Trends, Utilization)
8. ((anti?biotic? or anti?microbial?) adj3 (prescri* or consumption or utili?ation or usage or ‘use’ or dispens* 
or sale?)).ab,ti.
9. 5 or 6 or 7 or 8
Measurement 10. BENCHMARKING/cl, ec, mt, st, sn, td, ut (Classification, Economics, Methods, Standards, Statistics & 
Numerical Data, Trends, Utilization)
11. (intervention adj5 (prescri* or stewardship or ‘use’ or utili?ation or usage or consumption)).ab,ti
12. ((anti?biotic? or anti?microbial?) adj4 (estimat* or quanitf* or metric? or monitor* or surveillance or 
prevalence or survey or audit)).ab,ti.
13. (electronic prescri* or e?prescri*).ab,ti.
14. 10 or 11 or 12 or 13
Secondary care 15. Secondary care/
16. Hospitals/
17. hospital*.ab,ti.
18. 15 or 16 or 17
19. 4 and 9 and 14 and 18
ab, abstract; ti., title; adj3–5, indicates two words next to each other in any order with up to 2–4 words in between; /, indicates a Medical 
Subject Heading (MeSH); *, denotes any truncation; ?, denotes one character or no character. All other abbreviations are elaborated in 
parentheses in the table.
Table 2 An adaptation of the APEASE framework to assess the feasibility of metrics for use in routine surveillance
A (Affordability) Resources required to sustainably implement the metric. For example, person time to audit/new system 
roll-out.
P (Practicability) Can the metric be delivered? Is there sustainable access to data and resources?
E (Effectiveness) Does the surveillance method capture sufficient data?
A (Acceptability) Does it represent relevant data to monitor antibiotic usage and appropriateness of antibiotic usage?
S (Side-effects) Bias of metrics
E (Equity) Is it feasible for hospital trusts of varying levels of resources and digital maturity to all implement the 
surveillance methodology?
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and inappropriate antibiotic usage in hospitals. This 
will include a description of the teams most frequently 
involved in this type of work in order to identify those 
groups who are often facilitators of this surveillance.
This will then be used to consider each surveillance 
method within an adaptation of the APEASE framework 
to assess the practicality of each method and metric for use 
in routine surveillance of antibiotic usage; this method 
is detailed in ‘Data synthesis’.23 This aims to inform the 
methodology of sustainable antibiotic usage surveillance 
programmes. We will also document if it is stated that the 
metric is currently being routinely used for any purpose 
such as national level surveillance. This will identify 
reasons why antibiotic usage surveillance is already being 
implemented and combined with methodological details 
will reveal programmes where existing infrastructure may 
be extended for use to routinely monitor antibiotic usage 
within hospitals. If the metric has been used to define 
and estimate (in)appropriate antibiotic usage, this will 
be used to explore the variation in the definitions and 
estimates of inappropriate antibiotic usage in hospitals. It 
is anticipated that such estimations will have been made 
using a multitude of methodologies and measures. The 
extent to which quantitative estimates of inappropriate 
prescribing can be directly compared may therefore be 
limited.
Assessment of risk of bias in individual studies
All metrics of antibiotic consumption included in the 
final review must have been used in the secondary care 
setting to capture the antibiotic usage data for at least 100 
patients. This is to ensure some level of demonstration of 
the feasibility of implementing the measures. For these 
descriptive purposes, it is not appropriate to use a risk of 
bias framework.
For studies included in the full-text review stage and 
which attempt to make a quantitative estimate of appro-
priate or inappropriate antibiotic usage in the secondary 
care setting, the Newcastle-Ottawa scale to assess study 
quality will be used to determine the inclusion of the esti-
mate in the review.30
data synthesis
The data will undergo a descriptive synthesis to provide 
insight into the methodologies to implement antibi-
otic usage metrics in secondary care. We will record the 
frequency of use of different data sources by level (indi-
vidual to national) and by source (such as electronic 
prescribing or audits). This will examine the type of data 
which is currently being used to monitor antibiotic usage 
and consequently the level detail in which we are able to 
examine prescribing currently. We will also identify the 
frequency of use of each metric to measure: volume, type, 
duration, stewardship activity and prevalence/incidence 
of antibiotic use. As well as identify the level at which 
these metrics are most frequently presented such as by 
specialty or nationally. The teams involved in these studies 
to collect and analyse the data will also be recorded.
An adaptation of the APEASE framework will be used 
to assess the feasibility of metrics for use in routine moni-
toring of antibiotic usage. The APEASE framework was 
designed to aid the context-specific design and selection 
of interventions to promote health behaviour change.23 
This original framework will be adapted to inform the 
establishment of a consensus to monitor antibiotic usage 
in the high-income secondary care setting (table 2).
This analysis can then be used to inform recommenda-
tions based on the available literature regarding a sustain-
able, conventional strategy to monitor antibiotic usage 
and the resources which would be required to practically 
implement such a surveillance strategy.
The variation between comparable hospital-level esti-
mates of (in)appropriate antibiotic usage will be repre-
sented using a funnel plot of inappropriate prescribing 
estimates against patient numbers and 95% CIs.
Meta-bias(es)
The systematic review will be conducted in line with this 
protocol and any aspects of the method which deviate 
from the original protocol will be reported in the final 
review. Only articles written in English language will be 
included in this review; this is due to the language spoken 
by the authors.
Confidence in cumulative evidence
This is a descriptive review to consider the methodolo-
gies which have been used to measure antibiotic usage 
and to define appropriate and inappropriate antibiotic 
prescribing in hospitals. The methodologies will be 
considered in terms of the APEASE criteria and it is there-
fore not necessary to consider the quality of quantitative 
evidence for all studies. For observational studies which 
attempt to make a quantitative estimate of appropriate 
or inappropriate antibiotic usage in the secondary care 
setting, the Newcastle-Ottawa scale to assess study quality 
will be used to determine the inclusion of the estimate in 
the review.30
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